all glp 1 drugs New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks GLP-1 Agonists: Using Semaglutide, Tirzepatide,
Description
The company made this prediction on the timing of FDA approval as it announced top-line results of a Phase 3 study showing a nearly 16% overall weight loss over a 17-month period among people who have both Type 2 diabetes and obesity 1
A recent head-to-head clinical trial comparing Wegovy and Zepbound returned similar results
(4) Interventions (control group/experimental group)
Retatrutide includes GLP-1 activity, but it is not only a GLP-1 drug
What makes this approval especially interesting is convenience
Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension
